NEWS IN BRIEF

MS Pharma acquires Genepharm, expands chronic disease portfolio

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/PrathanChorruangsak)
(Image: Getty/PrathanChorruangsak)

Related tags: Generics, MS Pharma, Genepharm

Jordan-based MS Pharma announces the acquisition of the Greek generic manufacturer Genepharm, aiming to add cardiovascular, CNS and oncology products to its portfolio.

Genepharm develops, manufactures and out-licenses generic pharmaceutical products, focusing on conventional solids, sterile liquid and oncology oral solids, for a client base across 70 countries.

MS Pharma, which operates across the Middle East, Turkey and Africa, will acquire 100% of Genepharm’s shares, while it also announced plans to ‘significantly increase’ Genepharm’s development resources in Athens.

According to MS Pharma, through the acquisition the company aims to expand its geographic footprint and reach more customers in Europe.

In addition, MS Pharma intends to bolster its portfolio with cardiovascular, CNS and oncology products, while it stated that Genepharm's portfolio will be strengthened with sterile injectable products and biotechnology candidates.

According to the agreement, Genepharm’s management will remain with the business. The transaction is expected to close by the end of April 2019. The cost of MS Pharma’s investment was not disclosed.

MS Pharma employs over 2,000 people in its facilities in Algeria, Jordan, Saudi Arabia and Turkey and exports to over 20 countries.

Related news

Show more

Related products

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...